114 results on '"Sommer, Natascha"'
Search Results
2. Air travel in patients suffering from pulmonary hypertension-A prospective, multicentre study.
- Author
-
Yogeswaran A, Grimminger J, Tello K, Becker L, Seeger W, Grimminger F, Sommer N, Ghofrani HA, Lange TJ, Stadler S, Olsson K, Kamp JC, Rosenkranz S, Gerhardt F, Milger K, Barnikel M, Ulrich S, Saxer S, Grünig E, Harutynova S, Opitz C, Klose H, Wilkens H, Halank M, Heberling M, Gall H, and Richter MJ
- Abstract
The PEGASUS study is the first multicentric and prospective assessment of the safety of air travel flying in pulmonary hypertension (PH) (NCT03051763). Data of air travel from 60 patients with PH was available. No severe adverse events occurred. Nine patients self-reported mild adverse events during flight (13%), while after landing, 12 patients reported events (20%). Solely one patient (2%) had an adverse event leading to medical consultation. In patients with PH and World Health Organization functional classes II and III, air travel was safe., Competing Interests: Henning Gall reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen‐Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics outside the submitted work. Athiththan Yogeswaran reports non‐financialnonfinancial support from the University of Giessen during the conduct of the study. Natascha Sommer reports personal fees from Actelion outside the submitted work. Hossein A. Ghofrani reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and personal fees from Bayer, Actelion, Pfizer, Merck, GSK, and Takeda, grants and personal fees from Novartis, Bayer HealthCare, and Encysive/Pfizer, and grants from Aires, the German Research Foundation, Excellence Cluster Cardiopulmonary Research, and the German Ministry for Education and Research outside the submitted work. Werner Seeger reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and personal fees from Pfizer and Bayer Pharma AG outside the submitted work. Manuel J. Richter reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and grants from United Therapeutics, grants and personal fees from Bayer, and personal fees from Actelion, Mundipharma, Roche, and OMT outside the submitted work. Khodr Tello reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the study, and personal fees from Actelion and Bayer outside the submitted work. Heinrike Wilkens received fees for lectures and/or consultations from Actelion, AOP, Bayer, Biotest, Boehringer‐Ingelheim, Daiichi Sankyo, Ferrer, GSK, Janssen Cilag, and MSD outside the submitted work. Michael Halank reports personal fees from AstraZeneca, Janssen‐Cilag, and MSD outside the submitted work. Melanie Heberling reports personal fees from Janssen‐Cilag und MSD outside the submitted work. Dr. Ulrich receives research grants from the Swiss National Science Foundation, Zurich and Swiss Lung League, Orpha‐Swiss, Emdo Foundation and travel support, lecture fees, and advisory compensation from MSD SA, Orpha Swiss, Janssen SA, Novartis SA, all unrelated to the present work. Katrin Milger reports speaker and/or advisory board honoraria from AOP Pharma, Ferrer, Janssen, MSD. Tobias J. Lange reports personal fees from Acceleron Pharma, AstraZeneca, Bayer, Böhringer Ingelheim, Ferrer, Gossamer Bio, Janssen Cilag, MSD, Orphacare, and Pfizer. Stefan Stadler reports personal fees from Acceleron Pharma, AOP Health, Gossamer Bio, Janssen Cilag, MSD, and Pfizer. Jan C. Kamp is supported by PRACTIS—Clinician Scientist Program of Hannover Medical School, funded by the German Research Foundation, grant no. ME 3696/3‐1, KFO311— 286251789. Ekkehard Grünig has received fees for lectures and/or consultations from Actelion, Bayer/MSD, Ferrer, GEBRO, GSK, Janssen, and OMT. Research grants to his institution have been received from Acceleron, Actelion, BayerHealthCare, MSD, Bellerophon, GossamerBio, GSK, Janssen, Novartis, OMT, Pfizer, REATE, and United Therapeutics outside the submitted work. Satenik Harutynova has received support from Janssen, OMT, Bayer Pharma, GSK and speaker fees from Janssen and OMT outside submitted work. Karen Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, AOP, MSD, Ferrer, Janssen, and OMT. Research grants to her institution have been received from Actelion, all outside the submitted work. All other authors declare no conflicts of interest., (© 2024 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.)
- Published
- 2024
- Full Text
- View/download PDF
3. Hif1α-dependent mitochondrial acute O 2 sensing and signaling to myocyte Ca 2+ channels mediate arterial hypoxic vasodilation.
- Author
-
Moreno-Domínguez A, Colinas O, Arias-Mayenco I, Cabeza JM, López-Ogayar JL, Chandel NS, Weissmann N, Sommer N, Pascual A, and López-Barneo J
- Subjects
- Animals, Mice, Signal Transduction, Male, Hypoxia metabolism, Mice, Inbred C57BL, Arteries metabolism, Calcium Channels, L-Type metabolism, Calcium Channels, L-Type genetics, Mice, Knockout, Electron Transport, Calcium Channels metabolism, Calcium Channels genetics, Vasodilation, Mitochondria metabolism, Oxygen metabolism, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Hypoxia-Inducible Factor 1, alpha Subunit genetics
- Abstract
Vasodilation in response to low oxygen (O
2 ) tension (hypoxic vasodilation) is an essential homeostatic response of systemic arteries that facilitates O2 supply to tissues according to demand. However, how blood vessels react to O2 deficiency is not well understood. A common belief is that arterial myocytes are O2 -sensitive. Supporting this concept, it has been shown that the activity of myocyte L-type Ca2+ channels, the main ion channels responsible for vascular contractility, is reversibly inhibited by hypoxia, although the underlying molecular mechanisms have remained elusive. Here, we show that genetic or pharmacological disruption of mitochondrial electron transport selectively abolishes O2 modulation of Ca2+ channels and hypoxic vasodilation. Mitochondria function as O2 sensors and effectors that signal myocyte Ca2+ channels due to constitutive Hif1α-mediated expression of specific electron transport subunit isoforms. These findings reveal the acute O2 -sensing mechanisms of vascular cells and may guide new developments in vascular pharmacology., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
4. [Harmful health effects of flavors in e-cigarettes].
- Author
-
Sommer N, Franzen K, Andreas S, Pankow W, Kunstmann W, and Hanewinkel R
- Abstract
Background: Almost all e-cigarettes contain flavorings that make the product more attractive. In the evaluation of e-cigarettes on health, flavors have so far played a subordinate role., Method: Selective literature search in PubMed, supplemented by legal regulations on the use of flavors in e-cigarettes., Results: Flavors make it easier to start using e-cigarettes and have a consumption-promoting effect. Deeper inhalation increases nicotine uptake and the absorption of toxic substances from the e-cigarette liquid. For some flavors, pathological effects have been demonstrated in addition to other toxic components of the e-cigarette. To date, no toxicological analyses are available for the vast majority of flavors contained in e-cigarettes., Conclusions: The proven consumption-promoting effect and the health risks that can be extrapolated from preclinical data are significant for the political discussion of a ban on flavors for e-cigarettes, analogous to the ban on flavors in tobacco products already in force., Competing Interests: Klaas Franzen, Stefan Andreas, Wulf Pankow, Wilfried Kunstmann und Reiner Hanewinkel sind ehrenamtlich für das Aktionsbündnis Nichtrauchen tätig. Natascha Sommer erhielt für Ihre Forschung zu E-Zigaretten finanzielle Unterstützung der Balzan-Preis Forschungsgruppe des Deutschen Zentrums für Lungenforschung (DZL) – Erika von Mutius, Klaus F. Rabe, Werner Seeger und Tobias Welte., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Respiratory and Metabolic Responses of CD4 + T Cells to Acute Exercise and their Association with Cardiorespiratory Fitness.
- Author
-
Gebhardt K, Hebecker A, Honekamp C, Nolte S, Barthkuhn M, Wilhelm J, Klatt S, Weyh C, Sommer N, and Krüger K
- Abstract
Introduction: The study aimed to investigate to what extent acute endurance exercise, especially eccentric exercise and cardiorespiratory fitness affect the metabolic profile of CD4 + cells., Methods: 15 male, healthy adults aged between 20 and 33 years with a maximal oxygen uptake (VO 2max ) between 44 and 63 ml/kg/min performed a downhill run (DR) and a level run (LR) for 45 minutes at 70% of their VO 2max on a treadmill in a cross-over design. Blood samples were taken before (T0), directly after (T1), 3 hours after (T3), and 24 hours (T24) after each exercise for analyzing leukocyte numbers and cytokine levels. Isolated CD4 + cells were incubated for 4 hours in autologous resting versus 3 hours after exercise serum (T3 DR and T3 LR), and subsequently, cellular respiration, transcriptomic, and metabolomics profiles were measured., Results: The systemic immune inflammation index increased significantly after DR and LR at T1 and T3 (p < .001). In contrast, the transcriptomic and metabolic profile of CD4 + cells showed no significant alterations after incubation in T3 exercise serum. However, cardiorespiratory fitness positively correlated with the maximal mitochondrial respiration in CD4 + cells after incubation with T3 LR serum (r = .617, p = .033) and with gene expression of oxidative phosphorylation and levels of different metabolites. Similarly, VO 2max was associated with an anti-inflammatory profile on RNA level. Lower lactate, methylmalonic acid, and D-gluconic acid levels were found in CD4 + cells of participants with a high VO 2max (p < .001)., Conclusions: Acute exercise leads to a mild pro-inflammatory milieu with only small changes in the metabolic homeostasis of CD4 + cells. High cardiorespiratory fitness is associated with a metabolic shift to oxidative phosphorylation in CD4 + cells. Functional relevance of this metabolic shift needs to be further investigated., Competing Interests: Conflict of Interest and Funding Source: No conflicts of interest are declared., (Copyright © 2024 by the American College of Sports Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
6. Cellular ROS and Antioxidants: Physiological and Pathological Role.
- Author
-
Kozlov AV, Javadov S, and Sommer N
- Abstract
Reactive oxygen species (ROS) are highly reactive oxygen derivatives that include free radicals such as superoxide anion radical (O
2 •- ) and hydroxyl radical (HO• ), as well as non-radical molecules hydrogen peroxide (H2 O2 ), peroxynitrite (ONOO- ), and hypochlorous acid (HOCl) [...].- Published
- 2024
- Full Text
- View/download PDF
7. [Medical societies in Germany call for a ban on flavors in e-cigarettes - A Position Paper of the German Respiratory Society (DGP) in cooperation with other professional associations and organizations].
- Author
-
Rupp A, Sommer N, Andreas S, Pankow W, Hanewinkel R, Wienbergen H, Batra A, Sauerbruch T, Kardos P, Ulbricht S, Brinkmann F, Scheubel R, Vogelmeier C, and Windisch W
- Subjects
- Germany, Humans, Pulmonary Medicine legislation & jurisprudence, Electronic Nicotine Delivery Systems, Societies, Medical, Flavoring Agents
- Abstract
E-cigarettes are primarily used by teenagers and young adults. Flavors in e-cigarettes increase their attractiveness and encourage young people and adults to start using them. This exposes young people in particular to the risk of nicotine addiction and various toxic substances from the aerosol of e-cigarettes. There are indications that various flavors in e-cigarettes are harmful to health, although toxicological studies are still lacking for the majority of flavors. There is a need for independent scientific investigations in this area. The scientific societies involved are calling for a ban on flavors in e-cigarettes, a ban on disposable e-cigarettes, effective regulation of the sale of e-cigarettes and effective control and implementation of the provisions for the protection of minors., Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Subpopulations of regulatory T cells are associated with subclinical atherosclerotic plaques, levels of LDL, and cardiorespiratory fitness in the elderly.
- Author
-
Böttrich T, Bauer P, Gröβer V, Huber M, Raifer H, Frech T, Nolte S, Dombrowski T, Cemic F, Sommer N, Ringseis R, Eder K, Krüger K, and Weyh C
- Subjects
- Humans, Male, Cross-Sectional Studies, Middle Aged, Female, Aged, Risk Factors, Cholesterol, LDL blood, Atherosclerosis blood, Lipoproteins, LDL blood, Life Style, T-Lymphocytes, Regulatory immunology, Plaque, Atherosclerotic blood, Cardiorespiratory Fitness
- Abstract
Background: Atherosclerosis forms the pathological basis for the development of cardiovascular disease. Since pathological processes initially develop without clinically relevant symptoms, the identification of early markers in the subclinical stage plays an important role for initiating early interventions. There is evidence that regulatory T cells (Tregs) are involved in the development of atherosclerosis. Therefore, the present study aimed to identify and investigate associations with Tregs and their subsets in a cohort of healthy elderly individuals with and without subclinical atherosclerotic plaques (SAP). In addition, various lifestyle and risk factors, such as cardiorespiratory fitness, were investigated as associated signatures., Methods: A cross-sectional study was performed in 79 participants (male: n = 50; age = 63.6 ± 3.7 years; body mass index = 24.9 ± 3.1 kg/m²; mean ± SD) who had no previous diagnosis of chronic disease and were not taking medication. Ultrasound of the carotids to identify SAP, cardiovascular function measurement for vascular assessment and a cardiorespiratory fitness test to determine peak oxygen uptake were performed. Additionally, tests were conducted to assess blood lipids and determine glucose levels. Immunophenotyping of Tregs and their subtypes (resting (rTregs) and effector/memory (mTregs)) was performed by 8-chanel flow cytometry. Participants were categorized according to atherosclerotic plaque status. Linear and logistic regression models were used to analyze associations between parameters., Results: SAP was detected in a total of 29 participants. The participants with plaque were older (64.8 ± 3.6 years vs. 62.9 ± 3.5 years) and had higher peripheral systolic blood pressure (133.8 ± 14.7 mmHg vs. 125.8 ± 10.9 mmHg). The participants with SAP were characterized by a lower percentage of rTregs (28.8% ± 10.7% vs. 34.6% ± 10.7%) and a higher percentage of mTregs (40.3% ± 14.7% vs. 30.0% ± 11.9%). Multiple logistic regression identified age (odds ratio (OR) = 1.20 (95% confidence interval (95%CI): 1.01-1.42)) and mTregs (OR = 1.05 (95%CI: 1.02-1.10)) as independent risk factors for SAP. Stepwise linear regression could reveal an association of peak oxygen uptake (β = 0.441), low-density lipoprotein (LDL) (β = -0.096), and SAP (β = 6.733) with mTregs and LDL (β = 0.104) with rTregs., Conclusion: While at an early stage of SAP, the total proportion of Tregs gives no indication of vascular changes, this is indicated by a shift in the Treg subgroups. Factors such as serum LDL or cardiopulmonary fitness may be associated with this shift and may also be additional diagnostic indicators. This could be used to initiate lifestyle-based preventive measures at an early stage, which may have a protective effect against disease progression., (Copyright © 2023. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
9. [Harmful health effects of flavors in e-cigarettes].
- Author
-
Sommer N, Franzen K, Andreas S, Pankow W, Kunstmann W, and Hanewinkel R
- Subjects
- Humans, Nicotine adverse effects, Vaping adverse effects, Vaping legislation & jurisprudence, Electronic Nicotine Delivery Systems, Flavoring Agents
- Abstract
Background: Almost all e-cigarettes contain flavorings that make the product more attractive. In the evaluation of e-cigarettes on health, flavors have so far played a subordinate role., Method: Selective literature search in PubMed, supplemented by legal regulations on the use of flavors in e-cigarettes., Results: Flavors make it easier to start using e-cigarettes and have a consumption-promoting effect. Deeper inhalation increases nicotine uptake and the absorption of toxic substances from the e-cigarette liquid. For some flavors, pathological effects have been demonstrated in addition to other toxic components of the e-cigarette. To date, no toxicological analyses are available for the vast majority of flavors contained in e-cigarettes., Conclusions: The proven consumption-promoting effect and the health risks that can be extrapolated from preclinical data are significant for the political discussion of a ban on flavors for e-cigarettes, analogous to the ban on flavors in tobacco products already in force., Competing Interests: Klaas Franzen, Stefan Andreas, Wulf Pankow, Wilfried Kunstmann und Reiner Hanewinkel sind ehrenamtlich für das Aktionsbündnis Nichtrauchen tätig. Natascha Sommer erhielt für Ihre Forschung zu E-Zigaretten finanzielle Unterstützung der Balzan-Preis Forschungsgruppe des Deutschen Zentrums für Lungenforschung (DZL) – Erika von Mutius, Klaus F. Rabe, Werner Seeger und Tobias Welte., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Association of cardiorespiratory fitness level with vascular function and subclinical atherosclerosis in the elderly.
- Author
-
Größer V, Weyh C, Böttrich T, Frech T, Nolte S, Sommer N, Huber M, Eder K, Dörr O, Hoelscher S, Weber R, Akdogan E, Nef H, Most A, Hamm CW, Krüger K, and Bauer P
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Blood Pressure physiology, Pulse Wave Analysis, Ankle Brachial Index, Vascular Stiffness physiology, Cardiorespiratory Fitness physiology, Atherosclerosis physiopathology
- Abstract
Purpose: Physical exercise is crucial for healthy aging and plays a decisive role in the prevention of atherosclerotic cardiovascular disease (ASCVD). A higher level of cardiorespiratory fitness (CRF) in the elderly is associated with lower cardiovascular and all-cause mortality. This study investigated the association of CRF level with vascular function and cardiovascular risk factors in the elderly., Methods: We examined 79 apparently healthy and physically active subjects aged > 55 years (64 ± 4 years). Cardiovascular functional parameters assessed included brachial and central blood pressure (BP), pulse wave velocity (PWV), augmentation index (Aix), and ankle-brachial index. Sonography of the common carotid artery was performed. CRF level was determined by a cardiopulmonary exercise test, and everyday activity was quantified with an accelerometer., Results: All participants had a higher CRF level than the reported age-specific normative values. Twenty-nine subjects had subclinical atherosclerosis of the common carotid artery. Compared with participants without atherosclerosis, they were older (p = 0.007), displayed higher brachial systolic BP (p = 0.006), and higher central systolic BP (p = 0.014). Lower brachial (p = 0.036) and central (p = 0.003) systolic BP, lower PWV (p = 0.004), lower Aix (p < 0.001), lower body fat percentage (< 0.001), and lower LDL cholesterol (p = 0.005) were associated with a higher CRF level., Conclusions: In this cohort of healthy and physically active individuals, subjects with subclinical atherosclerosis displayed higher systolic brachial and central BP. A higher CRF level was associated with enhanced vascular function, consistent with an influence of CRF on both BP and vascular function in the elderly., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
11. [Tobacco cessation: one of the most effective medical measures].
- Author
-
Raspe M, Lo K, Sommer N, and Andreas S
- Subjects
- Nicotine therapeutic use, Nicotinic Agonists therapeutic use, Tobacco Use Cessation Devices, Smoking Cessation, Tobacco Use Cessation
- Abstract
Tobacco smoking is widespread in Germany. An increase in the number of teenagers and young adults that smoke has recently been a cause for concern. The high prevalence in Germany is contrasted by inadequate preventive measures compared to international standards. Smoking behavior should always be inquired about and documented in the same way as vital signs. All smokers, regardless of the reason for contact and motivation, should receive short, low-threshold advice, e.g. using the ABC approach (ask, brief advice, cessation). In addition to repeated advice and referral to further services, the use of nicotine replacement or drug therapy is essential for the success of quitting. The combination of long- and short-acting nicotine replacement products doubles the success rate. Electronic nicotine delivery systems are not recommended for smoking cessation., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
12. The Role of the Redox Enzyme p66Shc in Biological Aging of the Lung.
- Author
-
Castro CFG, Nardiello C, Hadzic S, Kojonazarov B, Kraut S, Gierhardt M, Schäffer J, Bednorz M, Quanz K, Heger J, Korfei M, Wilhelm J, Hecker M, Bartkuhn M, Arnhold S, Guenther A, Seeger W, Schulz R, Weissmann N, Sommer N, and Pak O
- Subjects
- Animals, Mice, Src Homology 2 Domain-Containing, Transforming Protein 1 genetics, Shc Signaling Adaptor Proteins genetics, X-Ray Microtomography, Oxidation-Reduction, Aging genetics, Lung diagnostic imaging
- Abstract
The mitochondrial adaptor protein p66Shc has been suggested to control life span in mice via the release of hydrogen peroxide. However, the role of p66Shc in lung aging remains unsolved. Thus, we investigated the effects of p66Shc
-/- on the aging of the lung and pulmonary circulation. In vivo lung and cardiac characteristics were investigated in p66Shc-/- and wild type (WT) mice at 3, 12, and 24 months of age by lung function measurements, micro-computed tomography (µCT), and echocardiography. Alveolar number and muscularization of small pulmonary arteries were measured by stereology and vascular morphometry, respectively. Protein and mRNA levels of senescent markers were measured by western blot and PCR, respectively. Lung function declined similarly in WT and p66Shc-/- mice during aging. However, µCT analyses and stereology showed slightly enhanced signs of aging-related parameters in p66Shc-/- mice, such as a decline of alveolar density. Accordingly, p66Shc-/- mice showed higher protein expression of the senescence marker p21 in lung homogenate compared to WT mice of the corresponding age. Pulmonary vascular remodeling was increased during aging, but aged p66Shc-/- mice showed similar muscularization of pulmonary vessels and hemodynamics like WT mice. In the heart, p66Shc-/- prevented the deterioration of right ventricular (RV) function but promoted the decline of left ventricular (LV) function during aging. p66Shc-/- affects the aging process of the lung and the heart differently. While p66Shc-/- slightly accelerates lung aging and deteriorates LV function in aged mice, it seems to exert protective effects on RV function during aging.- Published
- 2024
- Full Text
- View/download PDF
13. Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice.
- Author
-
Hadzic S, Wu CY, Gredic M, Pak O, Loku E, Kraut S, Kojonazarov B, Wilhelm J, Brosien M, Bednorz M, Seimetz M, Günther A, Kosanovic D, Sommer N, Warburton D, Li X, Grimminger F, Ghofrani HA, Schermuly RT, Seeger W, El Agha E, Bellusci S, and Weissmann N
- Subjects
- Humans, Animals, Mice, Pancreatic Elastase adverse effects, Pancreatic Elastase metabolism, Fibroblast Growth Factor 10 metabolism, Fibroblast Growth Factor 10 therapeutic use, Receptor, Fibroblast Growth Factor, Type 2 genetics, Receptor, Fibroblast Growth Factor, Type 2 metabolism, Receptor, Fibroblast Growth Factor, Type 2 therapeutic use, Lung metabolism, Mice, Inbred C57BL, Pulmonary Disease, Chronic Obstructive drug therapy, Hypertension, Pulmonary complications, Cigarette Smoking adverse effects, Pulmonary Emphysema etiology, Emphysema complications
- Abstract
Background: COPD is an incurable disease and a leading cause of death worldwide. In mice, fibroblast growth factor (FGF)10 is essential for lung morphogenesis, and in humans, polymorphisms in the human FGF10 gene correlate with an increased susceptibility to develop COPD., Methods: We analysed FGF10 signalling in human lung sections and isolated cells from healthy donor, smoker and COPD lungs. The development of emphysema and PH was investigated in Fgf10
+/- and Fgfr2b+/- (FGF receptor 2b) mice upon chronic exposure to cigarette smoke. In addition, we overexpressed FGF10 in mice following elastase- or cigarette smoke-induced emphysema and pulmonary hypertension (PH)., Results: We found impaired FGF10 expression in human lung alveolar walls and in primary interstitial COPD lung fibroblasts. In contrast, FGF10 expression was increased in large pulmonary vessels in COPD lungs. Consequently, we identified impaired FGF10 signalling in alveolar walls as an integral part of the pathomechanism that leads to emphysema and PH development: mice with impaired FGF10 signalling ( Fgf10+/- and Fgfr2b+/- ) spontaneously developed lung emphysema, PH and other typical pathomechanistic features that generally arise in response to cigarette smoke exposure., Conclusion: In a therapeutic approach, FGF10 overexpression successfully restored lung alveolar and vascular structure in mice with established cigarette smoke- and elastase-induced emphysema and PH. FGF10 treatment triggered an initial increase in the number of alveolar type 2 cells that gradually returned to the basal level when the FGF10-mediated repair process progressed. Therefore, the application of recombinant FGF10 or stimulation of the downstream signalling cascade might represent a novel therapeutic strategy in the future., Competing Interests: Conflict of interest: The authors have no potential conflicts of interest to disclose., (Copyright ©The authors 2023.)- Published
- 2023
- Full Text
- View/download PDF
14. [Pulmonary hypertension associated with lung disease].
- Author
-
Halank M, Zeder KE, Sommer N, Ulrich S, Held M, Köhler T, Foris V, Heberling M, Neurohr C, Ronczka J, Holt S, Skowasch D, Kneidinger N, and Behr J
- Subjects
- Humans, Lung, Vascular Resistance, Prognosis, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary etiology, Hypertension, Pulmonary therapy, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial therapy, Lung Diseases, Interstitial complications
- Abstract
Lung diseases and hypoventilation syndromes are often associated with pulmonary hypertension (PH). In most cases, PH is not severe. This is defined hemodynamically by a mean pulmonary arterial pressure (PAPm) > 20 mmHg, a pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance of ≤ 5 Wood units (WU). Both the non-severe (PVR ≤ 5 WU) and much more the severe PH (PVR > 5 WU) have an unfavorable prognosis.If PH is suspected, it is recommended to primarily check whether risk factors for pulmonary arterial hypertension (PAH, group 1 PH) or chronic thromboembolic pulmonary hypertension (CTEPH, group 4 PH) are present. If risk factors are present or there is a suspicion of severe PH in lung patients, it is recommended that the patient should be presented to a PH outpatient clinic promptly.For patients with severe PH associated with lung diseases, personalized, individual therapy is recommended - if possible within the framework of therapy studies. Currently, a therapy attempt with PH specific drugs should only be considered in COPD patients if the associated PH is severe and a "pulmonary vascular" phenotype (severe precapillary PH, but typically only mild to moderate airway obstruction, no or mild hypercapnia and DLCO < 45 % of predicted value) is present. In patients with severe PH associated with interstitial lung disease phosphodiesterase-5-inhibitors may be considered in individual cases. Inhaled treprostinil may be considered also in non-severe PH in this patient population., Competing Interests: M.H.: Honorare für Vortrags- und Beratertätigkeiten von AstraZeneca, Janssen und MSD. Reisekosten von Janssen. Alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.K.E.Z.: Reisekosten und Vortragstätigkeiten von Fa. MSD, Janssen und Ferrer. Alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.N.S.: Honorare für Berater- und Vortragstätigkeiten von MSD und Janssen. Alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.S.U.: Forschungsgelder vom Schweizerischen Nationalfond, der Lungenliga Schweiz, der Lunge Zürich, der Emdo Foundation, von Janssen SA, Orpha Swiss. Reisekosten und Vortragstätigkeiten von Janssen SA, Orpha Swiss, MSD und Novartis, alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.M.H.: Beratungshonorare: Actelion, Bayer Healthcare, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, MSD, Pfizer. Honorare für Vorträge von: Actelion, AstraZeneca, Bayer HealthCare, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Daichi Sankyo, Janssen, MSD, Pfizer, Santis.T.K.: Honorare für Vortragstätigkeiten und Reisekostenübernahme von AstraZeneca, Berlin Chemie, Janssen und MSD. Alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.V.F.: Honorare für Vortragstätigkeiten und Reisekostenübernahme von Boehringer Ingelheim, BMS, Chiesi, Janssen, MSD, alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.M.H.: keineC.N.: Honorare für Vortrags- und Beratertätigkeiten von AstraZeneca, Janssen und MSD. Alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.J.R.: keineS.H.: Zuwendungen von Janssen, Bayer und MSD, die in keinem Zusammenhang mit dieser Arbeit stehen.D.S.: Vortrags- und Beratungshonorare und/oder Forschungsunterstützung von AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GSK, Janssen, MSD, Sanofi, DFG, BMBF. Alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.N.K.: erhielt finanzielle Zuwendungen von Janssen, Ferrer, Bayer und MSD, die in keinem Zusammenhang mit dieser Arbeit stehen.J.B.: Honorare für Vorträge und Beratertätigkeit von AstraZeneca, Biogen, Boehringer-Ingelheim, BMS, Ferrer, Novartis, Roche, and Sanofi-Genzyme. Für Tätigkeiten im Rahmen von Data Monitoring and Safety Boards erhielt er Honorare von Actelion und Galapagos. Es besteht kein Zusammenhang mit der vorliegenden Publikation., (Thieme. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. [Genetic diagnostics and molecular approaches in pulmonary arterial hypertension].
- Author
-
Eichstaedt CA, Bikou O, Sommer N, Schermuly RT, Pullamsetti SS, Weissmann N, Harbaum L, Tabeling C, Wißmüller M, Foris V, Kuebler WM, Hinderhofer K, Olschewski A, and Kwapiszewska G
- Subjects
- Humans, Familial Primary Pulmonary Hypertension diagnosis, Familial Primary Pulmonary Hypertension genetics, Familial Primary Pulmonary Hypertension therapy, Pulmonary Arterial Hypertension, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary genetics, Hypertension, Pulmonary therapy, Pulmonary Veno-Occlusive Disease diagnosis, Pulmonary Veno-Occlusive Disease genetics, Pulmonary Veno-Occlusive Disease therapy
- Abstract
The recently published new European guidelines for diagnosis and treatment of pulmonary hypertension now offer the so far most extensive description of genetic testing and counselling for pulmonary arterial hypertension patients. In addition, the importance of a clinical screening of healthy mutation carriers is highlighted as well as the genetic testing of patients with a suspicion of pulmonary veno-occlusive disease. We frame the respective parts of the guidelines on genetic testing and counselling in the context of recent data and provide comments. Finally, we give an outlook on novel molecular approaches starting from Sotatercept, addressing ion channels and novel therapeutic developments., Competing Interests: C.A.E. und K.H. sind Erfinderinnen des europäischen Patentens (EP3507380) “Gene panel specific for pulmonary hypertension and its uses”. CAE hat von MSD Vortragshonorare erhalten, unabhängig von dieser Arbeit.N.S. hat Berater- und Vortragstätigkeiten für MSD und Janssen.R.T.S. erhielt Forschungsförderung von Gossamer.S.S.P. erhielt Forschungsgelder und Honorare von Gossamer Bio, Inc.N.W. ist Besitzer des Patentes: L-NIL als Inhibitor zur Regeneration der Lunge von an COPD leidenden Patienten (EP2591777B1).L.H. erhielt Vortragshonorare von Janssen-Cilag und AOP Health sowie Forschungsmittel von MSD.C.T. erhielt finanzielle Förderung für Forschung von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Bayer HealthCare, Boehringer Ingelheim, und für Vorträge und Beratungstätigkeit von Actelion Pharmaceuticals, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, GlaxoSmithKline, und nicht-finanzielle Förderung von Actelion, ALK-Abelló, Bayer HealthCare, Boehringer Ingelheim und GlaxoSmithKline.M.W. erhielt Vortragshonorare von Janssen.V.F. erhielt Reisekosten und Vortragstätigkeiten von Boehringer Ingelheim, BMS, Chiesi, Janssen, MSD, alle nicht im Zusammenhang mit der aktuellen Übersichtsarbeit.A.O. ist Erfinderin des Patentes (WO2017153472A1 priority date 09.03.2016, erteilt in US, KR, JP, pending in CA, EP, AU) “Biomarker for the diagnosis of pulmonary hypertension (PH)”, ohne daraus persönlichen Gewinn zu erhalten. A.O. hat Honorare für Präsentationen und Reiseförderung von MSD erhalten, unabhängig von dieser Arbeit.O.B., W.M.K., G.K. haben keinen Interessenkonflikt., (Thieme. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. Pulmonary Hypertension: A Contemporary Review.
- Author
-
Johnson S, Sommer N, Cox-Flaherty K, Weissmann N, Ventetuolo CE, and Maron BA
- Subjects
- Humans, Lung, Familial Primary Pulmonary Hypertension complications, Chronic Disease, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary epidemiology, Hypertension, Pulmonary etiology, Pulmonary Arterial Hypertension complications, Vascular Diseases, Pulmonary Embolism complications
- Abstract
Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH) associated with lung disease, and chronic thromboembolic PH cast new light on the pathogenetic mechanisms, epidemiology, diagnostic approach, and therapeutic armamentarium for pulmonary vascular disease. Here, we summarize key basic, translational, and clinical PH reports, emphasizing findings that build on current state-of-the-art research. This review includes cutting-edge progress in translational pulmonary vascular biology, with a guide to the diagnosis of patients in clinical practice, incorporating recent PH definition revisions that continue emphasis on early detection of disease. PH management is reviewed including an overview of the evolving considerations for the approach to treatment of PH in patients with cardiopulmonary comorbidities, as well as a discussion of the groundbreaking sotatercept data for the treatment of pulmonary arterial hypertension.
- Published
- 2023
- Full Text
- View/download PDF
17. n-3 Polyunsaturated Fatty Acids Modulate LPS-Induced ARDS and the Lung-Brain Axis of Communication in Wild-Type versus Fat-1 Mice Genetically Modified for Leukotriene B4 Receptor 1 or Chemerin Receptor 23 Knockout.
- Author
-
Hernandez J, Schäffer J, Herden C, Pflieger FJ, Reiche S, Körber S, Kitagawa H, Welter J, Michels S, Culmsee C, Bier J, Sommer N, Kang JX, Mayer K, Hecker M, and Rummel C
- Subjects
- Animals, Mice, Brain, Chromatography, Liquid, Inflammation, Lipopolysaccharides toxicity, Lung, Mice, Knockout, Receptors, Leukotriene B4, Tandem Mass Spectrometry, Fatty Acids, Omega-3, Respiratory Distress Syndrome chemically induced, Respiratory Distress Syndrome genetics
- Abstract
Specialized pro-resolving mediators (SPMs) and especially Resolvin E1 (RvE1) can actively terminate inflammation and promote healing during lung diseases such as acute respiratory distress syndrome (ARDS). Although ARDS primarily affects the lung, many ARDS patients also develop neurocognitive impairments. To investigate the connection between the lung and brain during ARDS and the therapeutic potential of SPMs and its derivatives, fat-1 mice were crossbred with RvE1 receptor knockout mice. ARDS was induced in these mice by intratracheal application of lipopolysaccharide (LPS, 10 µg). Mice were sacrificed at 0 h, 4 h, 24 h, 72 h, and 120 h post inflammation, and effects on the lung, liver, and brain were assessed by RT-PCR, multiplex, immunohistochemistry, Western blot, and LC-MS/MS. Protein and mRNA analyses of the lung, liver, and hypothalamus revealed LPS-induced lung inflammation increased inflammatory signaling in the hypothalamus despite low signaling in the periphery. Neutrophil recruitment in different brain structures was determined by immunohistochemical staining. Overall, we showed that immune cell trafficking to the brain contributed to immune-to-brain communication during ARDS rather than cytokines. Deficiency in RvE1 receptors and enhanced omega-3 polyunsaturated fatty acid levels ( fat-1 mice) affect lung-brain interaction during ARDS by altering profiles of several inflammatory and lipid mediators and glial activity markers.
- Published
- 2023
- Full Text
- View/download PDF
18. Nicotine promotes e-cigarette vapour-induced lung inflammation and structural alterations.
- Author
-
Roxlau ET, Pak O, Hadzic S, Garcia-Castro CF, Gredic M, Wu CY, Schäffer J, Selvakumar B, Pichl A, Spiegelberg D, Deutscher J, Bednorz M, Schäfer K, Kraut S, Kosanovic D, Zeidan EM, Kojonazarov B, Herold S, Strielkov I, Guenther A, Wilhelm J, Khalifa MMA, Taye A, Brandes RP, Hecker M, Grimminger F, Ghofrani HA, Schermuly RT, Seeger W, Sommer N, and Weissmann N
- Subjects
- Humans, Animals, Mice, Nicotine adverse effects, Lung metabolism, Plant Extracts metabolism, Plant Extracts pharmacology, Electronic Nicotine Delivery Systems, E-Cigarette Vapor adverse effects, E-Cigarette Vapor metabolism, Pneumonia etiology, Pneumonia metabolism
- Abstract
Background: Electronic cigarette (e-cigarette) vapour is gaining popularity as an alternative to tobacco smoking and can induce acute lung injury. However, the specific role of nicotine in e-cigarette vapour and its long-term effects on the airways, lung parenchyma and vasculature remain unclear., Results: In vitro exposure to nicotine-containing e-cigarette vapour extract (ECVE) or to nicotine-free e-cigarette vapour extract (NF ECVE) induced changes in gene expression of epithelial cells and pulmonary arterial smooth muscle cells (PASMCs), but ECVE in particular caused functional alterations ( e.g. a decrease in human and mouse PASMC proliferation by 29.3±5.3% and 44.3±8.4%, respectively). Additionally, acute inhalation of nicotine-containing e-cigarette vapour (ECV) but not nicotine-free e-cigarette vapour (NF ECV) increased pulmonary endothelial permeability in isolated lungs. Long-term in vivo exposure of mice to ECV for 8 months significantly increased the number of inflammatory cells, in particular lymphocytes, compared to control and NF ECV in the bronchoalveolar fluid (BALF) (ECV: 853.4±150.8 cells·mL
-1 ; control: 37.0±21.1 cells·mL-1 ; NF ECV: 198.6±94.9 cells·mL-1 ) and in lung tissue (ECV: 25.7±3.3 cells·mm-3 ; control: 4.8±1.1 cells·mm-3 ; NF ECV: 14.1±2.2 cells·mm-3 ). BALF cytokines were predominantly increased by ECV. Moreover, ECV caused significant changes in lung structure and function ( e.g. increase in airspace by 17.5±1.4% compared to control), similar to mild tobacco smoke-induced alterations, which also could be detected in the NF ECV group, albeit to a lesser degree. In contrast, the pulmonary vasculature was not significantly affected by ECV or NF ECV., Conclusions: NF ECV components induce cell type-specific effects and mild pulmonary alterations, while inclusion of nicotine induces significant endothelial damage, inflammation and parenchymal alterations., Competing Interests: Conflict of interest: All authors have nothing to disclose., (Copyright ©The authors 2023.)- Published
- 2023
- Full Text
- View/download PDF
19. CEACAM6 as a Novel Therapeutic Target to Boost HO-1-mediated Antioxidant Defense in COPD.
- Author
-
Wu CY, Cilic A, Pak O, Dartsch RC, Wilhelm J, Wujak M, Lo K, Brosien M, Zhang R, Alkoudmani I, Witte B, Pedersen F, Watz H, Voswinckel R, Günther A, Ghofrani HA, Brandes RP, Schermuly RT, Grimminger F, Seeger W, Sommer N, Weissmann N, and Hadzic S
- Subjects
- Humans, Antigens, CD metabolism, Antioxidants, Cell Adhesion Molecules metabolism, GPI-Linked Proteins adverse effects, GPI-Linked Proteins metabolism, Heme Oxygenase-1 metabolism, Oxidative Stress, Nicotiana, Emphysema, Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
- Abstract
Rationale: Tobacco smoking and air pollution are primary causes of chronic obstructive pulmonary disease (COPD). However, only a minority of smokers develop COPD. The mechanisms underlying the defense against nitrosative/oxidative stress in nonsusceptible smokers to COPD remain largely unresolved. Objectives: To investigate the defense mechanisms against nitrosative/oxidative stress that possibly prevent COPD development or progression. Methods: Four cohorts were investigated: 1 ) sputum samples (healthy, n = 4; COPD, n = 37), 2 ) lung tissue samples (healthy, n = 13; smokers without COPD, n = 10; smoker+COPD, n = 17), 3 ) pulmonary lobectomy tissue samples (no/mild emphysema, n = 6), and 4 ) blood samples (healthy, n = 6; COPD, n = 18). We screened 3-nitrotyrosine (3-NT) levels, as indication of nitrosative/oxidative stress, in human samples. We established a novel in vitro model of a cigarette smoke extract (CSE)-resistant cell line and studied 3-NT formation, antioxidant capacity, and transcriptomic profiles. Results were validated in lung tissue, isolated primary cells, and an ex vivo model using adeno-associated virus-mediated gene transduction and human precision-cut lung slices. Measurements and Main Results: 3-NT levels correlate with COPD severity of patients. In CSE-resistant cells, nitrosative/oxidative stress upon CSE treatment was attenuated, paralleled by profound upregulation of heme oxygenase-1 (HO-1). We identified carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) as a negative regulator of HO-1-mediated nitrosative/oxidative stress defense in human alveolar type 2 epithelial cells (hAEC2s). Consistently, inhibition of HO-1 activity in hAEC2s increased the susceptibility toward CSE-induced damage. Epithelium-specific CEACAM6 overexpression increased nitrosative/oxidative stress and cell death in human precision-cut lung slices on CSE treatment. Conclusions: CEACAM6 expression determines the hAEC2 sensitivity to nitrosative/oxidative stress triggering emphysema development/progression in susceptible smokers.
- Published
- 2023
- Full Text
- View/download PDF
20. Estimated plasma volume status: association with congestion, cardiorenal syndrome and prognosis in precapillary pulmonary hypertension.
- Author
-
Yogeswaran A, Richter MJ, Husain-Syed F, Rako Z, Sommer N, Grimminger F, Seeger W, Ghofrani HA, Gall H, and Tello K
- Abstract
Background: Volume overload is often associated with clinical deterioration in precapillary pulmonary hypertension (PH). However, thorough assessment of volume overload is complex and therefore not routinely performed. We examined whether estimated plasma volume status (ePVS) is associated with central venous congestion and prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH) or chronic thromboembolic PH (CTEPH)., Methods: We included all patients with incident IPAH or CTEPH enrolled in the Giessen PH Registry between January 2010 and January 2021. Plasma volume status was estimated using the Strauss formula., Results: In total, 381 patients were analyzed. Patients with high ePVS (≥4.7 vs. <4.7 ml/g) at baseline showed significantly increased central venous pressure (CVP; median [Q1, Q3]: 8 [5, 11] mmHg vs. 6 [3, 10] mmHg) and pulmonary arterial wedge pressure (10 [8, 15] mmHg vs. 8 [6, 12] mmHg), while right ventricular function was not altered. In multivariate stepwise backward Cox regression, ePVS was independently associated with transplant-free survival at baseline and during follow-up (hazard ratio [95% confidence interval]: 1.24 [0.96, 1.60] and 2.33 [1.49, 3.63], respectively). An intra-individual decrease in ePVS was associated with a decrease in CVP and predicted prognosis in univariate Cox regression. Patients with high ePVS without edema had lower transplant-free survival than those with normal ePVS without edema. In addition, high ePVS was associated with cardiorenal syndrome., Conclusions: In precapillary PH, ePVS is associated with congestion and prognosis. High ePVS without edema may represent an under-recognized subgroup with poor prognosis., Competing Interests: AY reports personal fees from MSD outside the submitted work. KT reports personal fees from Actelion and Bayer outside the submitted work. NS reports personal fees from Actelion outside the submitted work. WS reports personal fees from Pfizer and Bayer Pharma AG outside the submitted work. HAG reports personal fees from Bayer, Actelion, Pfizer, Merck, GSK, and Takeda, grants and personal fees from Novartis, Bayer HealthCare, and Encysive/Pfizer, and grants from Aires outside the submitted work. HG reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics outside the submitted work. MR reports grants from United Therapeutics, grants and personal fees from Bayer, and personal fees from Actelion, Mundipharma, Roche, and OMT outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Yogeswaran, Richter, Husain-Syed, Rako, Sommer, Grimminger, Seeger, Ghofrani, Gall and Tello.)
- Published
- 2023
- Full Text
- View/download PDF
21. Decreased plasma levels of the brain-derived neurotrophic factor correlate with right heart congestion in pulmonary arterial hypertension.
- Author
-
Schäfer K, Tello K, Pak O, Richter M, Gierhardt M, Kwapiszewska G, Veith C, Fink L, Gall H, Hecker M, Kojonazarov B, Kraut S, Lo K, Wilhelm J, Grimminger F, Seeger W, Schermuly RT, Ghofrani HA, Zahner D, Gerstberger R, Weissmann N, Sydykov A, and Sommer N
- Abstract
Background: The brain-derived neurotrophic factor (BDNF) may promote development of pulmonary hypertension and right ventricular (RV) failure. However, BDNF plasma levels were decreased in patients with left ventricular (LV) failure. Therefore, we investigated BDNF plasma levels in pulmonary hypertension patients and the role of BDNF in mouse models of pulmonary hypertension and isolated RV failure., Methods: BDNF plasma levels were correlated to pulmonary hypertension in two patient cohorts, including either post- and pre-capillary pulmonary hypertension patients (first cohort) or only pre-capillary pulmonary hypertension patients (second cohort). In the second cohort, RV dimensions and load-independent function were determined by imaging and pressure-volume catheter measurements, respectively. For induction of isolated RV pressure overload, heterozygous Bdnf knockout ( Bdnf
+/- ) mice were subjected to pulmonary arterial banding (PAB). For induction of pulmonary hypertension, mice with inducible knockout of BDNF in smooth muscle cells ( Bdnf / Smmhc knockout) were exposed to chronic hypoxia., Results: Plasma BDNF levels were decreased in patients with pulmonary hypertension. Following adjustment for covariables, BDNF levels negatively correlated in both cohorts with central venous pressure. In the second cohort, BDNF levels additionally negatively correlated with RV dilatation. In animal models, BDNF downregulation attenuated RV dilatation in Bdnf+ / - mice after PAB or hypoxic Bdnf / Smmhc knockout mice, although they developed pulmonary hypertension to a similar extent., Conclusions: Similar to LV failure, circulating levels of BDNF were decreased in pulmonary hypertension patients, and low BDNF levels were associated with right heart congestion. Decreased BDNF levels did not worsen RV dilatation in animal models, and thus, may be the consequence, but not the cause of RV dilatation., Competing Interests: Conflict of interest: No disclosures., (Copyright ©The authors 2023.)- Published
- 2023
- Full Text
- View/download PDF
22. iNOS Deletion in Alveolar Epithelium Cannot Reverse the Elastase-Induced Emphysema in Mice.
- Author
-
Gredic M, Sharma V, Hadzic S, Wu CY, Pak O, Kojonazarov B, Duerr J, Mall MA, Guenther A, Schermuly RT, Grimminger F, Seeger W, Kraut S, Sommer N, and Weissmann N
- Subjects
- Mice, Swine, Animals, Pancreatic Elastase metabolism, Nitric Oxide Synthase Type II metabolism, Epithelium metabolism, Pulmonary Emphysema chemically induced, Pulmonary Emphysema metabolism, Emphysema
- Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. In addition to chronic bronchitis and emphysema, patients often develop at least mild pulmonary hypertension (PH). We previously demonstrated that inhibition of inducible nitric oxide synthase (iNOS) prevents and reverses emphysema and PH in mice. Interestingly, strong iNOS upregulation was found in alveolar epithelial type II cells (AECII) in emphysematous murine lungs, and peroxynitrite, which can be formed from iNOS-derived NO, was shown to induce AECII apoptosis in vitro. However, the specific cell type(s) that drive(s) iNOS-dependent lung regeneration in emphysema/PH has (have) not been identified yet., Aim: we tested whether iNOS knockout in AECII affects established elastase-induced emphysema in mice., Methods: four weeks after a single intratracheal instillation of porcine pancreatic elastase for the induction of emphysema and PH, we induced iNOS knockout in AECII in mice, and gave an additional twelve weeks for the potential recovery., Results: iNOS knockout in AECII did not reduce elastase-induced functional and structural lung changes such as increased lung compliance, decreased mean linear intercept and increased airspace, decreased right ventricular function, increased right ventricular systolic pressure and increased pulmonary vascular muscularization. In vitro, iNOS inhibition did not reduce apoptosis of AECII following exposure to a noxious stimulus., Conclusion: taken together, our data demonstrate that iNOS deletion in AECII is not sufficient for the regeneration of emphysematous murine lungs, and suggest that iNOS expression in pulmonary vascular or stromal cells might be critically important in this regard.
- Published
- 2022
- Full Text
- View/download PDF
23. Alternative oxidase encoded by sequence-optimized and chemically-modified RNA transfected into mammalian cells is catalytically active.
- Author
-
Giordano L, Aneja MK, Sommer N, Alebrahimdehkordi N, Seraji A, Weissmann N, Rudolph C, Plank C, Jacobs HT, and Szibor M
- Subjects
- Animals, Humans, Mice, Fibroblasts metabolism, Mitochondrial Proteins genetics, Mitochondrial Proteins metabolism, A549 Cells, Transfection, Mitochondria genetics, Mitochondria metabolism, RNA metabolism
- Abstract
Plants and other organisms, but not insects or vertebrates, express the auxiliary respiratory enzyme alternative oxidase (AOX) that bypasses mitochondrial respiratory complexes III and/or IV when impaired. Persistent expression of AOX from Ciona intestinalis in mammalian models has previously been shown to be effective in alleviating some metabolic stresses produced by respiratory chain inhibition while exacerbating others. This implies that chronic AOX expression may modify or disrupt metabolic signaling processes necessary to orchestrate adaptive remodeling, suggesting that its potential therapeutic use may be confined to acute pathologies, where a single course of treatment would suffice. One possible route for administering AOX transiently is AOX-encoding nucleic acid constructs. Here we demonstrate that AOX-encoding chemically-modified RNA (cmRNA), sequence-optimized for expression in mammalian cells, was able to support AOX expression in immortalized mouse embryonic fibroblasts (iMEFs), human lung carcinoma cells (A549) and primary mouse pulmonary arterial smooth muscle cells (PASMCs). AOX protein was detectable as early as 3 h after transfection, had a half-life of ~4 days and was catalytically active, thus supporting respiration and protecting against respiratory inhibition. Our data demonstrate that AOX-encoding cmRNA optimized for use in mammalian cells represents a viable route to investigate and possibly treat mitochondrial respiratory disorders., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
24. Mitochondrial oxygen sensing of acute hypoxia in specialized cells - Is there a unifying mechanism?
- Author
-
Pak O, Nolte A, Knoepp F, Giordano L, Pecina P, Hüttemann M, Grossman LI, Weissmann N, and Sommer N
- Subjects
- Humans, Hypoxia, Protein Isoforms, Reactive Oxygen Species metabolism, Electron Transport Complex IV metabolism, Oxygen metabolism
- Abstract
Acclimation to acute hypoxia through cardiorespiratory responses is mediated by specialized cells in the carotid body and pulmonary vasculature to optimize systemic arterial oxygenation and thus oxygen supply to the tissues. Acute oxygen sensing by these cells triggers hyperventilation and hypoxic pulmonary vasoconstriction which limits pulmonary blood flow through areas of low alveolar oxygen content. Oxygen sensing of acute hypoxia by specialized cells thus is a fundamental pre-requisite for aerobic life and maintains systemic oxygen supply. However, the primary oxygen sensing mechanism and the question of a common mechanism in different specialized oxygen sensing cells remains unresolved. Recent studies unraveled basic oxygen sensing mechanisms involving the mitochondrial cytochrome c oxidase subunit 4 isoform 2 that is essential for the hypoxia-induced release of mitochondrial reactive oxygen species and subsequent acute hypoxic responses in both, the carotid body and pulmonary vasculature. This review compares basic mitochondrial oxygen sensing mechanisms in the pulmonary vasculature and the carotid body., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Correction: Sommer et al. Decreased Thymic Output Contributes to Immune Defects in Septic Patients. J. Clin. Med. 2020, 9 , 2695.
- Author
-
Sommer N, Noack S, Hecker A, Hackstein H, Bein G, Weissmann N, Seeger W, Mayer K, and Hecker M
- Abstract
In the original article, there were errors in Figure 1D (panel CD8-Control) [...].
- Published
- 2022
- Full Text
- View/download PDF
26. [Pulmonary manifestations in long COVID].
- Author
-
Sommer N and Schmeck B
- Subjects
- Humans, Lung diagnostic imaging, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications, Lung Diseases, Interstitial diagnosis
- Abstract
Background: Pulmonary manifestations are very common sequelae after severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections, which are summarized under the term long COVID (coronavirus disease) syndrome., Aim/methods: This article summarizes the current literature on pulmonary manifestations with a focus on expert opinions and recommendations., Results: After chronic fatigue, dyspnea is the most common symptom in patients with long COVID syndrome. Pathological findings are mainly found after a severe acute course of COVID-19 and include radiological changes with characteristics of interstitial lung diseases, restrictive ventilation patterns and limitations in diffusion capacity as the most common pathological finding. Although both symptoms and pathological pulmonary alterations improve over time, some patients may still suffer from abnormalities months after the acute infection. The relevance of the pathological findings, as well as the involvement of functional respiratory limitations, cardiopulmonary deconditioning, non-somatic causes and pre-existing lung diseases, is currently unclear. The advanced diagnostic assessment thus focusses on high-risk patients and includes, in addition to imaging and pulmonary function tests, a cardiopulmonary exercise test and, if the findings are unclear, an echocardiography to diagnose a pulmonary vascular component. The therapeutic options currently include treatment of the underlying causes of the symptoms (e.g. interstitial lung diseases, cough) according to the respective guidelines and rehabilitation measures., Discussion: The current knowledge about pulmonary manifestations in long COVID patients is constantly being expanded, but due to limited availability of clinical trials, there are still no evidence-based guidelines for the diagnosis and therapy of pulmonary manifestations in long COVID syndrome., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
27. Chronic Lung Allograft Dysfunction Is Associated with Increased Levels of Cell-Free Mitochondrial DNA in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients.
- Author
-
Schneck E, Askevold I, Rath R, Hecker A, Reichert M, Guth S, Koch C, Sander M, Seeger W, Mayer K, Padberg W, Sommer N, Kuhnert S, and Hecker M
- Abstract
Chronic Lung Allograft Dysfunction (CLAD) is a life-threatening complication that limits the long-term survival of lung transplantation patients. Early diagnosis remains the basis of efficient management of CLAD, making the need for distinctive biomarkers critical. This explorative study aimed to investigate the predictive power of mitochondrial DNA (mtDNA) derived from bronchoalveolar lavages (BAL) to detect CLAD. The study included 106 lung transplant recipients and analyzed 286 BAL samples for cell count, cell differentiation, and inflammatory and mitochondrial biomarkers, including mtDNA. A receiver operating curve analysis of mtDNA levels was used to assess its ability to detect CLAD. The results revealed a discriminatory pro-inflammatory cytokine profile in the BAL fluid of CLAD patients. The concentration of mtDNA increased in step with each CLAD stage, reaching its highest concentration in stage 4, and correlated significantly with decreasing FEV1. The receiver operating curve analysis of mtDNA in BAL revealed a moderate prediction of CLAD when all stages were grouped together (AUROC 0.75, p-value < 0.0001). This study has found the concentration mtDNA in BAL to be a potential predictor for the early detection of CLAD and the differentiation of different CLAD stages, independent of the underlying pathology.
- Published
- 2022
- Full Text
- View/download PDF
28. Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension.
- Author
-
Sommer N, Theine FF, Pak O, Tello K, Richter M, Gall H, Wilhelm J, Savai R, Weissmann N, Seeger W, Ghofrani HA, and Hecker M
- Abstract
Mitochondrial and immune cell dysfunction contributes to the development of pulmonary arterial hypertension (PAH). We thus aimed to investigate mitochondrial respiration and mitochondrial gene expression patterns in the peripheral blood mononuclear cells (PBMC) of patients with idiopathic and hereditary PAH and their correlation to disease parameters. Mitochondrial respiration determined using high-resolution respirometry was not significantly different in PBMC when comparing an outpatient cohort of PAH patients with healthy controls. However, when directly comparing mitochondrial respiration to the hemodynamic parameters of an inpatient PAH cohort, mitochondrial respiration negatively correlated with pulmonary vascular resistance (PVR) and positively correlated with the cardiac index (CI). Furthermore, microarray analysis shows upregulation of mitochondrial erythroid-specific 5-aminolevulinate synthase 2 (ALAS2), as well as the regulation of genes involved in iron and heme metabolism, in the PBMC of patients with PAH, with ALAS2 upregulation in PAH patients being confirmed on the protein level. Multiple regression analysis with age and gender as confounders showed that both PVR and hemoglobin content negatively correlated with maximal respiration. Therefore, we conclude that mitochondrial function in the PBMC of PAH patients is affected by disease severity. However, further studies to investigate cell-type-specific alterations and functional consequences are necessary.
- Published
- 2022
- Full Text
- View/download PDF
29. Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD.
- Author
-
Kuhnert S, Mansouri S, Rieger MA, Savai R, Avci E, Díaz-Piña G, Padmasekar M, Looso M, Hadzic S, Acker T, Klatt S, Wilhelm J, Fleming I, Sommer N, Weissmann N, Vogelmeier C, Bals R, Zeiher A, Dimmeler S, Seeger W, and Pullamsetti SS
- Subjects
- Aged, Gene Expression, Hematopoiesis genetics, Humans, Mutation genetics, Clonal Hematopoiesis, Pulmonary Disease, Chronic Obstructive genetics
- Abstract
Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations (~20%) with a predominance of DNMT3A CHIP-mediated hypomethylation of Phospholipase D Family Member 5 ( PLD5 ), which in turn is positively correlated with increased levels of glycerol phosphocholine, pro-inflammatory cytokines, and deteriorating lung function.
- Published
- 2022
- Full Text
- View/download PDF
30. Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice.
- Author
-
Gredic M, Wu CY, Hadzic S, Pak O, Savai R, Kojonazarov B, Doswada S, Weiss A, Weigert A, Guenther A, Brandes RP, Schermuly RT, Grimminger F, Seeger W, Sommer N, Kraut S, and Weissmann N
- Subjects
- Animals, Humans, Hypoxia, Macrophages metabolism, Mice, Mice, Knockout, Nitric Oxide metabolism, Nitric Oxide Synthase Type II metabolism, Smoke adverse effects, Nicotiana metabolism, Vascular Remodeling, Emphysema, Hypertension, Pulmonary chemically induced, Hypertension, Pulmonary prevention & control, Pulmonary Emphysema
- Abstract
Background: Pulmonary hypertension (PH) is a common complication of COPD, associated with increased mortality and morbidity. Intriguingly, pulmonary vascular alterations have been suggested to drive emphysema development. Previously, we identified inducible nitric oxide synthase (iNOS) as an essential enzyme for development and reversal of smoke-induced PH and emphysema, and showed that iNOS expression in bone-marrow-derived cells drives pulmonary vascular remodelling, but not parenchymal destruction. In this study, we aimed to identify the iNOS-expressing cell type driving smoke-induced PH and to decipher pro-proliferative pathways involved., Methods: To address this question we used 1) myeloid-cell-specific iNOS knockout mice in chronic smoke exposure and 2) co-cultures of macrophages and pulmonary artery smooth muscle cells (PASMCs) to decipher underlying signalling pathways., Results: Myeloid-cell-specific iNOS knockout prevented smoke-induced PH but not emphysema in mice. Moreover, iNOS deletion in myeloid cells ameliorated the increase in expression of CD206, a marker of M2 polarisation, on interstitial macrophages. Importantly, the observed effects on lung macrophages were hypoxia-independent, as these mice developed hypoxia-induced PH. In vitro , smoke-induced PASMC proliferation in co-cultures with M2-polarised macrophages could be abolished by iNOS deletion in phagocytic cells, as well as by extracellular signal-regulated kinase inhibition in PASMCs. Crucially, CD206-positive and iNOS-positive macrophages accumulated in proximity of remodelled vessels in the lungs of COPD patients, as shown by immunohistochemistry., Conclusion: In summary, our results demonstrate that iNOS deletion in myeloid cells confers protection against PH in smoke-exposed mice and provide evidence for an iNOS-dependent communication between M2-like macrophages and PASMCs in underlying pulmonary vascular remodelling., Competing Interests: Conflict of interest: M. Gredic has nothing to disclose. Conflict of interest: C-Y. Wu has nothing to disclose. Conflict of interest: S. Hadzic has nothing to disclose. Conflict of interest: O. Pak has nothing to disclose. Conflict of interest: R. Savai has nothing to disclose. Conflict of interest: B. Kojonazarov has nothing to disclose. Conflict of interest: S. Doswada has nothing to disclose. Conflict of interest: A. Weiss has nothing to disclose. Conflict of interest: A. Weigert has nothing to disclose. Conflict of interest: A. Guenther has nothing to disclose. Conflict of interest: R.P. Brandes has nothing to disclose. Conflict of interest: R.T. Schermuly has nothing to disclose. Conflict of interest: F. Grimminger has nothing to disclose. Conflict of interest: W. Seeger reports personal fees from Actelion, Bayer AG, Novartis, Vectura, Medspray and United Therapeutics, outside the submitted work. Conflict of interest: N. Sommer reports personal fees from Actelion, outside the submitted work. Conflict of interest: S. Kraut has nothing to disclose. Conflict of interest: N. Weissmann reports grants from the German Research Foundation, during the conduct of the study; and has a patent L-NIL as inhibitor for regenerating the lung of a patient suffering from COPD (EP2591777A2) issued., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
31. Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension.
- Author
-
Eichstaedt CA, Saßmannshausen Z, Shaukat M, Cao D, Xanthouli P, Gall H, Sommer N, Ghofrani HA, Seyfarth HJ, Lerche M, Halank M, Kleymann J, Benjamin N, Harutyunova S, Egenlauf B, Milger K, Rosenkranz S, Ewert R, Klose H, Hoeper MM, Olsson KM, Lankeit M, Lange TJ, Hinderhofer K, and Grünig E
- Subjects
- Activin Receptors, Type II genetics, Adenosine Triphosphatases genetics, Familial Primary Pulmonary Hypertension diagnosis, Familial Primary Pulmonary Hypertension epidemiology, Familial Primary Pulmonary Hypertension genetics, Genetic Predisposition to Disease genetics, Humans, Membrane Transport Proteins genetics, Mutation genetics, Protein Serine-Threonine Kinases, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary genetics, Hypertension, Pulmonary pathology, Pulmonary Arterial Hypertension diagnosis, Pulmonary Arterial Hypertension genetics
- Abstract
Background: A genetic predisposition can lead to the rare disease pulmonary arterial hypertension (PAH). Most mutations have been identified in the gene BMPR2 in heritable PAH. However, as of today 15 further PAH genes have been described. The exact prevalence across these genes particularly in other PAH forms remains uncertain. We present the distribution of mutations across PAH genes identified at the largest German referral centre for genetic diagnostics in PAH over a course of > 3 years., Methods: Our PAH-specific gene diagnostics panel was used to sequence 325 consecutive PAH patients from March 2017 to October 2020. For the first year the panel contained thirteen PAH genes: ACVRL1, BMPR1B, BMPR2, CAV1, EIF2AK4, ENG, GDF2, KCNA5, KCNK3, KLF2, SMAD4, SMAD9 and TBX4. These were extended by the three genes ATP13A3, AQP1 and SOX17 from March 2018 onwards following the genes' discovery., Results: A total of 79 mutations were identified in 74 patients (23%). Of the variants 51 (65%) were located in the gene BMPR2 while the other 28 variants were found in ten further PAH genes. We identified disease-causing variants in the genes AQP1, KCNK3 and SOX17 in families with at least two PAH patients. Mutations were not only detected in patients with heritable and idiopathic but also with associated PAH., Conclusions: Genetic defects were identified in 23% of the patients in a total of 11 PAH genes. This illustrates the benefit of the specific gene panel containing all known PAH genes., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
32. SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension.
- Author
-
Veith C, Vartürk-Özcan I, Wujak M, Hadzic S, Wu CY, Knoepp F, Kraut S, Petrovic A, Gredic M, Pak O, Brosien M, Heimbrodt M, Wilhelm J, Weisel FC, Malkmus K, Schäfer K, Gall H, Tello K, Kosanovic D, Sydykov A, Sarybaev A, Günther A, Brandes RP, Seeger W, Grimminger F, Ghofrani HA, Schermuly RT, Kwapiszewska G, Sommer N, and Weissmann N
- Subjects
- Animals, Cell Proliferation, Cells, Cultured, Endothelial Cells metabolism, Familial Primary Pulmonary Hypertension metabolism, Humans, Hypoxia metabolism, Mice, Mice, Inbred C57BL, Myocytes, Smooth Muscle metabolism, Osteonectin genetics, Pulmonary Artery, Vascular Remodeling genetics, Hypertension, Pulmonary pathology
- Abstract
Background: Pulmonary hypertension (PH) is a life-threatening disease, characterized by excessive pulmonary vascular remodeling, leading to elevated pulmonary arterial pressure and right heart hypertrophy. PH can be caused by chronic hypoxia, leading to hyper-proliferation of pulmonary arterial smooth muscle cells (PASMCs) and apoptosis-resistant pulmonary microvascular endothelial cells (PMVECs). On reexposure to normoxia, chronic hypoxia-induced PH in mice is reversible. In this study, the authors aim to identify novel candidate genes involved in pulmonary vascular remodeling specifically in the pulmonary vasculature., Methods: After microarray analysis, the authors assessed the role of SPARC (secreted protein acidic and rich in cysteine) in PH using lung tissue from idiopathic pulmonary arterial hypertension (IPAH) patients, as well as from chronically hypoxic mice. In vitro studies were conducted in primary human PASMCs and PMVECs. In vivo function of SPARC was proven in chronic hypoxia-induced PH in mice by using an adeno-associated virus-mediated Sparc knockdown approach., Results: C57BL/6J mice were exposed to normoxia, chronic hypoxia, or chronic hypoxia with subsequent reexposure to normoxia for different time points. Microarray analysis of the pulmonary vascular compartment after laser microdissection identified Sparc as one of the genes downregulated at all reoxygenation time points investigated. Intriguingly, SPARC was vice versa upregulated in lungs during development of hypoxia-induced PH in mice as well as in IPAH, although SPARC plasma levels were not elevated in PH. TGF-β1 (transforming growth factor β1) or HIF2A (hypoxia-inducible factor 2A) signaling pathways induced SPARC expression in human PASMCs. In loss of function studies, SPARC silencing enhanced apoptosis and reduced proliferation. In gain of function studies, elevated SPARC levels induced PASMCs, but not PMVECs, proliferation. Coculture and conditioned medium experiments revealed that PMVECs-secreted SPARC acts as a paracrine factor triggering PASMCs proliferation. Contrary to the authors' expectations, in vivo congenital Sparc knockout mice were not protected from hypoxia-induced PH, most probably because of counter-regulatory proproliferative signaling. However, adeno-associated virus-mediated Sparc knockdown in adult mice significantly improved hemodynamic and cardiac function in PH mice., Conclusions: This study provides evidence for the involvement of SPARC in the pathogenesis of human PH and chronic hypoxia-induced PH in mice, most likely by affecting vascular cell function.
- Published
- 2022
- Full Text
- View/download PDF
33. Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters.
- Author
-
Yogeswaran A, Tello K, Lund J, Klose H, Harbaum L, Sommer N, Oqueka T, Hennigs JK, Grimminger F, Seeger W, Ghofrani HA, Richter MJ, and Gall H
- Subjects
- Adult, Aged, Biomarkers blood, Chronic Disease, Familial Primary Pulmonary Hypertension blood, Familial Primary Pulmonary Hypertension epidemiology, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Assessment, Survival Rate, Hypertension, Pulmonary blood, Hypertension, Pulmonary epidemiology, Pulmonary Embolism blood, Pulmonary Embolism epidemiology
- Abstract
Background: γ-glutamyl transferase (GGT), the aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, and the neutrophil-to-lymphocyte ratio (NLR) are prognostic biomarkers in several cardiovascular diseases, but their relevance in pulmonary hypertension (PH) is not fully understood. We aimed to assess their prognostic value in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH)., Methods: We retrospectively analyzed 731 incident patients with idiopathic PAH or CTEPH who entered the Giessen PH registry during 1993-2019. A risk stratification score based on GGT, AST/ALT ratio, and NLR tertiles was compared with a truncated version of the European Society of Cardiology/European Respiratory Society (ESC/ERS) risk stratification scheme. Associations with survival were evaluated using Kaplan-Meier and Cox regression analyses. External validation was performed in 311 patients with various types of PAH or CTEPH from a second German center., Results: GGT levels, AST/ALT, and NLR independently predicted mortality at baseline and during follow-up. The scoring system based on these biomarkers predicted mortality at baseline and during follow-up (both log-rank p < 0.001; hazard ratio [95% confidence interval], high vs low risk: baseline, 7.6 [3.9, 15.0]; follow-up, 13.3 [4.8, 37.1]). Five-year survival of low, intermediate, and high risk groups was 92%, 76%, and 51%, respectively, at baseline and 95%, 78%, and 50%, respectively, during follow-up. Our scoring system showed characteristics comparable to the ESC/ERS scheme, and predicted mortality in the validation cohort., Conclusion: GGT, AST/ALT, and NLR were reliable prognostic biomarkers at baseline and during follow-up, with predictive power comparable to the gold standard for risk stratification., Competing Interests: Disclosure statement Mr Yogeswaran, Dr Tello, Mr Lund, Dr Klose, Dr Harbaum, Dr Sommer, Dr Oqueka, Dr Hennigs, and Dr Grimminger have declared no conflict of interest. Dr Seeger has received speaker/consultancy fees/fees for participation in advisory boards from Pfizer, Novartis, United Therapeutics, Actelion, Vectura, Savara, Medspray, and Bayer Pharma AG. Dr Ghofrani has received consultancy fees from Bayer, Actelion, Pfizer, Merck, GSK, and Novartis; fees for participation in advisory boards from Bayer, Pfizer, GSK, Actelion, and Takeda; lecture fees from Bayer HealthCare, GSK, Actelion, and Encysive/Pfizer; industry-sponsored grants from Bayer HealthCare, Aires, Encysive/Pfizer, and Novartis; and sponsored grants from the German Research Foundation, Excellence Cluster Cardiopulmonary Research, and the German Ministry for Education and Research. Dr Richter has received support from United Therapeutics and Bayer Pharma AG, and speaker fees from Actelion, Mundipharma, Roche, and OMT. Dr Gall has received fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics., (Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. Endogenous formaldehyde scavenges cellular glutathione resulting in redox disruption and cytotoxicity.
- Author
-
Umansky C, Morellato AE, Rieckher M, Scheidegger MA, Martinefski MR, Fernández GA, Pak O, Kolesnikova K, Reingruber H, Bollini M, Crossan GP, Sommer N, Monge ME, Schumacher B, and Pontel LB
- Subjects
- Aldehyde Oxidoreductases genetics, Animals, Caenorhabditis elegans, Caenorhabditis elegans Proteins genetics, DNA Damage, Disease Models, Animal, Fanconi Anemia genetics, Fanconi Anemia Complementation Group D2 Protein genetics, Fanconi Anemia Complementation Group D2 Protein metabolism, Formaldehyde metabolism, Gene Knockout Techniques, HCT116 Cells, Humans, Oxidation-Reduction, Oxidative Stress, Aldehyde Oxidoreductases metabolism, Caenorhabditis elegans Proteins metabolism, Fanconi Anemia metabolism, Formaldehyde toxicity, Glutathione metabolism
- Abstract
Formaldehyde (FA) is a ubiquitous endogenous and environmental metabolite that is thought to exert cytotoxicity through DNA and DNA-protein crosslinking, likely contributing to the onset of the human DNA repair condition Fanconi Anaemia. Mutations in the genes coding for FA detoxifying enzymes underlie a human inherited bone marrow failure syndrome (IBMFS), even in the presence of functional DNA repair, raising the question of whether FA causes relevant cellular damage beyond genotoxicity. Here, we report that FA triggers cellular redox imbalance in human cells and in Caenorhabditis elegans. Mechanistically, FA reacts with the redox-active thiol group of glutathione (GSH), altering the GSH:GSSG ratio and causing oxidative stress. FA cytotoxicity is prevented by the enzyme alcohol dehydrogenase 5 (ADH5/GSNOR), which metabolizes FA-GSH products, lastly yielding reduced GSH. Furthermore, we show that GSH synthesis protects human cells from FA, indicating an active role of GSH in preventing FA toxicity. These findings might be relevant for patients carrying mutations in FA-detoxification systems and could suggest therapeutic benefits from thiol-rich antioxidants like N-acetyl-L-cysteine., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. Systemic Effects of mitoTEMPO upon Lipopolysaccharide Challenge Are Due to Its Antioxidant Part, While Local Effects in the Lung Are Due to Triphenylphosphonium.
- Author
-
Weidinger A, Birgisdóttir L, Schäffer J, Meszaros AT, Zavadskis S, Müllebner A, Hecker M, Duvigneau JC, Sommer N, and Kozlov AV
- Abstract
Mitochondria-targeted antioxidants (mtAOX) are a promising treatment strategy against reactive oxygen species-induced damage. Reports about harmful effects of mtAOX lead to the question of whether these could be caused by the carrier molecule triphenylphosphonium (TPP). The aim of this study was to investigate the biological effects of the mtAOX mitoTEMPO, and TPP in a rat model of systemic inflammatory response. The inflammatory response was induced by lipopolysaccharide (LPS) injection. We show that mitoTEMPO reduced expression of inducible nitric oxide synthase in the liver, lowered blood levels of tissue damage markers such as liver damage markers (aspartate aminotransferase and alanine aminotransferase), kidney damage markers (urea and creatinine), and the general organ damage marker, lactate dehydrogenase. In contrast, TPP slightly, but not significantly, increased the LPS-induced effects. Surprisingly, both mitoTEMPO and TPP reduced the wet/dry ratio in the lung after 24 h. In the isolated lung, both substances enhanced the increase in pulmonary arterial pressure induced by LPS observed within 3 h after LPS treatments but did not affect edema formation at this time. Our data suggest that beneficial effects of mitoTEMPO in organs are due to its antioxidant moiety (TEMPO), except for the lung where its effects are mediated by TPP.
- Published
- 2022
- Full Text
- View/download PDF
36. Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone.
- Author
-
Gierhardt M, Pak O, Sydykov A, Kraut S, Schäffer J, Garcia C, Veith C, Zeidan EM, Brosien M, Quanz K, Esfandiary A, Saraji A, Hadzic S, Kojonazarov B, Wilhelm J, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F, Herden C, Schulz R, Weissmann N, Heger J, and Sommer N
- Subjects
- Animals, Calcium Signaling, Cell Proliferation, Cells, Cultured, Peptidyl-Prolyl Isomerase F genetics, Disease Models, Animal, Gene Deletion, Hypertension, Pulmonary etiology, Hypertension, Pulmonary genetics, Hypertension, Pulmonary physiopathology, Hypoxia complications, Mice, Inbred C57BL, Mice, Knockout, Mitochondria genetics, Mitochondrial Permeability Transition Pore metabolism, Pulmonary Artery physiopathology, Src Homology 2 Domain-Containing, Transforming Protein 1 genetics, Vascular Remodeling, Vascular Resistance, Mice, Arterial Pressure, Calcium metabolism, Peptidyl-Prolyl Isomerase F deficiency, Hypertension, Pulmonary enzymology, Mitochondria enzymology, Pulmonary Artery enzymology, Src Homology 2 Domain-Containing, Transforming Protein 1 deficiency, Vasoconstriction
- Abstract
Aims: The pulmonary vascular tone and hypoxia-induced alterations of the pulmonary vasculature may be regulated by the mitochondrial membrane permeability transition pore (mPTP) that controls mitochondrial calcium load and apoptosis. We thus investigated, if the mitochondrial proteins p66shc and cyclophilin D (CypD) that regulate mPTP opening affect the pulmonary vascular tone., Methods and Results: Mice deficient for p66shc (p66shc-/-), CypD (CypD-/-), or both proteins (p66shc/CypD-/-) exhibited decreased pulmonary vascular resistance (PVR) compared to wild-type mice determined in isolated lungs and in vivo. In contrast, systemic arterial pressure was only lower in CypD-/- mice. As cardiac function and pulmonary vascular remodelling did not differ between genotypes, we determined alterations of vascular contractility in isolated lungs and calcium handling in pulmonary arterial smooth muscle cells (PASMC) as underlying reason for decreased PVR. Potassium chloride (KCl)-induced pulmonary vasoconstriction and KCl-induced cytosolic calcium increase determined by Fura-2 were attenuated in all gene-deficient mice. In contrast, KCl-induced mitochondrial calcium increase determined by the genetically encoded Mito-Car-GECO and calcium retention capacity were increased only in CypD-/- and p66shc/CypD-/- mitochondria indicating that decreased mPTP opening affected KCl-induced intracellular calcium peaks in these cells. All mouse strains showed a similar pulmonary vascular response to chronic hypoxia, while acute hypoxic pulmonary vasoconstriction was decreased in gene-deficient mice indicating that CypD and p66shc regulate vascular contractility but not remodelling., Conclusions: We conclude that p66shc specifically regulates the pulmonary vascular tone, while CypD also affects systemic pressure. However, only CypD acts via regulation of mPTP opening and mitochondrial calcium regulation., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
37. Mitochondrien als universelle Sensoren der akuten Hypoxie?
- Author
-
Nolte A, Pak O, and Sommer N
- Abstract
Adaptation to acute hypoxia through cardiorespiratory responses is mediated by specialized cells in the carotid body and pulmonary vasculature to optimize systemic arterial oxygenation. Acute oxygen sensing thus is a fundamental pre-requisite for aerobic life. Recent studies unravelled basic oxygen sensing mechanisms involving the mitochondrial cytochrome c oxidase subunit 4 isoform 2 that regulates the release of mitochondrial reactive oxygen species and subsequent acute hypoxic responses., (© Die Autorinnen und Autoren 2022.)
- Published
- 2022
- Full Text
- View/download PDF
38. Experimental Setup for Investigation of Acute Mitochondrial Oxygen Sensing in Primary Cells.
- Author
-
Knoepp F, Weissmann N, Sommer N, and Szibor M
- Subjects
- Humans, Hypoxia metabolism, Mitochondria metabolism, Pulmonary Artery metabolism, Reactive Oxygen Species metabolism, Oxygen metabolism, Vasoconstriction physiology
- Abstract
The ability to sense and respond to acute changes in oxygen is essential for the viability of cells and organisms. To study molecular mechanisms of acute oxygen sensing, we established a setup for the adjustment of acute hypoxic conditions in cultured cells, exemplified here for the use of primary pulmonary arterial smooth muscle cells (PASMCs). The mitochondrial electron transport chain (ETC) is the main consumer of oxygen but recently also emerged as essential oxygen sensor suggesting that the ETC itself adapts its electron flux to oxygen availability. To test this assumption and to experimentally manipulate electron flux through the ETC, we used alternative oxidase (AOX), which bypasses the cytochrome pathway of the ETC when blocked. The described combination of our experimental setup and AOX allowed us in previous publications unprecedented insights into the role of the ETC in cellular oxygen sensing and cellular response mechanisms in living cells. Against this background, we here describe and discuss this method in detail, which will allow transfer to other cell types and research questions., (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
39. A Microfluidic System for Simultaneous Raman Spectroscopy, Patch-Clamp Electrophysiology, and Live-Cell Imaging to Study Key Cellular Events of Single Living Cells in Response to Acute Hypoxia.
- Author
-
Knoepp F, Wahl J, Andersson A, Kraut S, Sommer N, Weissmann N, and Ramser K
- Subjects
- Animals, Biosensing Techniques instrumentation, Cell Hypoxia, Cells, Cultured, Equipment Design, Membrane Potentials, Mice, Muscle, Smooth, Vascular metabolism, Patch-Clamp Techniques, Pulmonary Artery metabolism, Single-Cell Analysis, Spectrum Analysis, Raman, Biosensing Techniques methods, Microfluidic Analytical Techniques instrumentation, Muscle, Smooth, Vascular cytology, Oxygen analysis, Pulmonary Artery cytology
- Abstract
The ability to sense changes in oxygen availability is fundamentally important for the survival of all aerobic organisms. However, cellular oxygen sensing mechanisms and pathologies remain incompletely understood and studies of acute oxygen sensing, in particular, have produced inconsistent results. Current methods cannot simultaneously measure the key cellular events in acute hypoxia (i.e., changes in redox state, electrophysiological properties, and mechanical responses) at controlled partial pressures of oxygen (pO
2 ). The lack of such a comprehensive method essentially contributes to the discrepancies in the field. A sealed microfluidic system that combines i) Raman spectroscopy, ii) patch-clamp electrophysiology, and iii) live-cell imaging under precisely controlled pO2 have therefore been developed. Merging these modalities allows label-free and simultaneous observation of oxygen-dependent alterations in multiple cellular redox couples, membrane potential, and cellular contraction. This technique is adaptable to any cell type and allows in-depth insight into acute oxygen sensing processes underlying various physiologic and pathologic conditions., (© 2021 The Authors. Small Methods published by Wiley-VCH GmbH.)- Published
- 2021
- Full Text
- View/download PDF
40. Epigenetic Regulation by Suv4-20h1 in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease.
- Author
-
Qi H, Liu H, Pullamsetti SS, Günther S, Kuenne C, Atzberger A, Sommer N, Hadzic S, Günther A, Weissmann N, Zhou Y, Yuan X, and Braun T
- Subjects
- Animals, Humans, Mice, Mice, Knockout, Epigenesis, Genetic genetics, Histone-Lysine N-Methyltransferase metabolism, Hypertension, Pulmonary genetics, Pulmonary Disease, Chronic Obstructive genetics, Stem Cells metabolism
- Abstract
Background: The pathogenesis of life-threatening cardiopulmonary diseases such as pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD) originates from a complex interplay of environmental factors and genetic predispositions that is not fully understood. Likewise, little is known about developmental abnormalities or epigenetic dysregulations that might predispose for PH or COPD in adult individuals., Methods: To identify pathology-associated epigenetic alteration in diseased lung tissues, we screened a cohort of human patients with PH and COPD for changes of histone modifications by immunofluorescence staining. To analyze the function of H4K20me2/3 in lung pathogenesis, we developed a series of Suv4-20h1 knockout mouse lines targeting cardiopulmonary progenitor cells and different heart and lung cell types, followed by hemodynamic studies and morphometric assessment of tissue samples. Molecular, cellular, and biochemical techniques were applied to analyze the function of Suv4-20h1-dependent epigenetic processes in cardiopulmonary progenitor cells and their derivatives., Results: We discovered a strong reduction of the histone modifications of H4K20me2/3 in human patients with COPD but not patients with PH that depend on the activity of the H4K20 di-methyltransferase SUV4-20H1. Loss of Suv4-20h1 in cardiopulmonary progenitor cells caused a COPD-like/PH phenotype in mice including the formation of perivascular tertiary lymphoid tissue and goblet cell hyperplasia, hyperproliferation of smooth muscle cells/myofibroblasts, impaired alveolarization and maturation defects of the microvasculature leading to massive right ventricular dilatation and premature death. Mechanistically, SUV4-20H1 binds directly to the 5'-upstream regulatory element of the superoxide dismutase 3 ( Sod3 ) gene to repress its expression. Increased levels of the extracellular SOD3 enzyme in Suv4-20h1 mutants increases hydrogen peroxide concentrations, causing vascular defects and impairing alveolarization., Conclusions: Our findings reveal a pivotal role of the histone modifier SUV4-20H1 in cardiopulmonary codevelopment and uncover the developmental origins of cardiopulmonary diseases. We assume that the study will facilitate the understanding of pathogenic events causing PH and COPD and aid the development of epigenetic drugs for the treatment of cardiopulmonary diseases.
- Published
- 2021
- Full Text
- View/download PDF
41. Adenylate Kinase 4-A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1α Signaling Pathways.
- Author
-
Wujak M, Veith C, Wu CY, Wilke T, Kanbagli ZI, Novoyatleva T, Guenther A, Seeger W, Grimminger F, Sommer N, Schermuly RT, and Weissmann N
- Subjects
- Cell Hypoxia, Cells, Cultured, Familial Primary Pulmonary Hypertension metabolism, Familial Primary Pulmonary Hypertension pathology, Glycolysis, Humans, Muscle, Smooth, Vascular pathology, Myocytes, Smooth Muscle pathology, Pulmonary Artery pathology, Adenylate Kinase metabolism, Cell Proliferation, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle metabolism, Proto-Oncogene Proteins c-akt metabolism, Pulmonary Artery metabolism, Signal Transduction
- Abstract
Increased proliferation of pulmonary arterial smooth muscle cells (PASMCs) in response to chronic hypoxia contributes to pulmonary vascular remodeling in pulmonary hypertension (PH). PH shares numerous similarities with cancer, including a metabolic shift towards glycolysis. In lung cancer, adenylate kinase 4 (AK4) promotes metabolic reprogramming and metastasis. Against this background, we show that AK4 regulates cell proliferation and energy metabolism of primary human PASMCs. We demonstrate that chronic hypoxia upregulates AK4 in PASMCs in a hypoxia-inducible factor-1α (HIF-1α)-dependent manner. RNA interference of AK4 decreases the viability and proliferation of PASMCs under both normoxia and chronic hypoxia. AK4 silencing in PASMCs augments mitochondrial respiration and reduces glycolytic metabolism. The observed effects are associated with reduced levels of phosphorylated protein kinase B (Akt) as well as HIF-1α, indicating the existence of an AK4-HIF-1α feedforward loop in hypoxic PASMCs. Finally, we show that AK4 levels are elevated in pulmonary vessels from patients with idiopathic pulmonary arterial hypertension (IPAH), and AK4 silencing decreases glycolytic metabolism of IPAH-PASMCs. We conclude that AK4 is a new metabolic regulator in PASMCs interacting with HIF-1α and Akt signaling pathways to drive the pro-proliferative and glycolytic phenotype of PH.
- Published
- 2021
- Full Text
- View/download PDF
42. Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome.
- Author
-
Gierhardt M, Pak O, Walmrath D, Seeger W, Grimminger F, Ghofrani HA, Weissmann N, Hecker M, and Sommer N
- Subjects
- Humans, Hypoxia, Lung physiopathology, SARS-CoV-2, Vasoconstriction, COVID-19 complications, Respiratory Distress Syndrome diagnosis, Respiratory Distress Syndrome etiology, Respiratory Distress Syndrome therapy
- Abstract
Acute respiratory distress syndrome (ARDS) is a serious complication of severe systemic or local pulmonary inflammation, such as caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ARDS is characterised by diffuse alveolar damage that leads to protein-rich pulmonary oedema, local alveolar hypoventilation and atelectasis. Inadequate perfusion of these areas is the main cause of hypoxaemia in ARDS. High perfusion in relation to ventilation (V/Q<1) and shunting (V/Q=0) is not only caused by impaired hypoxic pulmonary vasoconstriction but also redistribution of perfusion from obstructed lung vessels. Rebalancing the pulmonary vascular tone is a therapeutic challenge. Previous clinical trials on inhaled vasodilators (nitric oxide and prostacyclin) to enhance perfusion to high V/Q areas showed beneficial effects on hypoxaemia but not on mortality. However, specific patient populations with pulmonary hypertension may profit from treatment with inhaled vasodilators. Novel treatment targets to decrease perfusion in low V/Q areas include epoxyeicosatrienoic acids and specific leukotriene receptors. Still, lung protective ventilation and prone positioning are the best available standard of care. This review focuses on disturbed perfusion in ARDS and aims to provide basic scientists and clinicians with an overview of the vascular alterations and mechanisms of V/Q mismatch, current therapeutic strategies, and experimental approaches., Competing Interests: Conflict of interest: M. Gierhardt has nothing to disclose. Conflict of interest: O. Pak has nothing to disclose. Conflict of interest: D. Walmrath has nothing to disclose. Conflict of interest: W. Seeger reports personal fees from Actelion, Bayer AG, Abivax, Vectura, Medspray, United Therapeutics and Liquidia, outside the submitted work. Conflict of interest: F. Grimminger has nothing to disclose. Conflict of interest: H.A. Ghofrani has nothing to disclose. Conflict of interest: N. Weissmann has nothing to disclose. Conflict of interest: M. Hecker has nothing to disclose. Conflict of interest: N. Sommer has nothing to disclose., (Copyright ©The authors 2021.)
- Published
- 2021
- Full Text
- View/download PDF
43. New Avenues for Antiinflammatory Signaling of Nur77 in Acute Lung Injury.
- Author
-
Sommer N, Pak O, and Hecker M
- Subjects
- Humans, Signal Transduction, Acute Lung Injury, Nuclear Receptor Subfamily 4, Group A, Member 1 genetics, Nuclear Receptor Subfamily 4, Group A, Member 1 metabolism
- Published
- 2021
- Full Text
- View/download PDF
44. Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model.
- Author
-
Mamazhakypov A, Sommer N, Assmus B, Tello K, Schermuly RT, Kosanovic D, Sarybaev AS, Weissmann N, and Pak O
- Subjects
- Animals, Disease Models, Animal, Humans, Pulmonary Artery, Ventricular Function, Right, Ventricular Remodeling, Hypertension, Pulmonary drug therapy, Ventricular Dysfunction, Right
- Abstract
Right ventricular (RV) function is the main determinant of the outcome of patients with pulmonary hypertension (PH). RV dysfunction develops gradually and worsens progressively over the course of PH, resulting in RV failure and premature death. Currently, approved therapies for the treatment of left ventricular failure are not established for the RV. Furthermore, the direct effects of specific vasoactive drugs for treatment of pulmonary arterial hypertension (PAH, Group 1 of PH) on RV are not fully investigated. Pulmonary artery banding (PAB) allows to study the pathogenesis of RV failure solely, thereby testing potential therapies independently of pulmonary vascular changes. This review aims to discuss recent studies of the mechanisms of RV remodeling and RV-directed therapies based on the PAB model.
- Published
- 2021
- Full Text
- View/download PDF
45. PINK1-mediated Mitophagy Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension.
- Author
-
Saraji A, Sydykov A, Schäfer K, Garcia-Castro CF, Henneke I, Alebrahimdehkordi N, Kosanovic D, Hadzic S, Guenther A, Hecker M, Ghofrani HA, Seeger W, Schermuly RT, Weissmann N, Sommer N, and Pak O
- Subjects
- Animals, Humans, Hypertension, Pulmonary genetics, Hypertension, Pulmonary pathology, Mice, Mice, Knockout, Protein Kinases genetics, Hypertension, Pulmonary enzymology, Mitophagy, Protein Kinases metabolism, Vascular Remodeling
- Published
- 2021
- Full Text
- View/download PDF
46. Metabolic Reprogramming in Congenital Cyanotic Heart Disease: Another Fight in Puberty?
- Author
-
Sommer N, Weissmann N, and Ghofrani HA
- Subjects
- Humans, Puberty, Cyanosis, Heart Defects, Congenital
- Published
- 2021
- Full Text
- View/download PDF
47. The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension.
- Author
-
Hadzic S, Wu CY, Gredic M, Kojonazarov B, Pak O, Kraut S, Sommer N, Kosanovic D, Grimminger F, Schermuly RT, Seeger W, Bellusci S, and Weissmann N
- Subjects
- Animals, Disease Models, Animal, Humans, Mice, Mice, Transgenic, Time Factors, Cigarette Smoking drug therapy, Cigarette Smoking genetics, Cigarette Smoking metabolism, Cigarette Smoking pathology, Doxycycline pharmacology, Hypertension, Pulmonary drug therapy, Hypertension, Pulmonary genetics, Hypertension, Pulmonary metabolism, Hypertension, Pulmonary pathology, Pulmonary Emphysema drug therapy, Pulmonary Emphysema genetics, Pulmonary Emphysema metabolism, Pulmonary Emphysema pathology
- Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of death and a still incurable disease, comprising emphysema and chronic bronchitis. In addition to airflow limitation, patients with COPD can suffer from pulmonary hypertension (PH). Doxycycline, an antibiotic from the tetracycline family, in addition to its pronounced antimicrobial activity, acts as a matrix metalloproteinase (MMP) inhibitor and has anti-inflammatory properties. Furthermore, doxycycline treatment exhibited a beneficial effect in several preclinical cardiovascular disease models. In preclinical research, doxycycline is frequently employed for gene expression modulation in Tet-On/Tet-Off transgenic animal models. Therefore, it is crucial to know whether doxycycline treatment in Tet-On/Tet-Off systems has effects independent of gene expression modulation by such systems. Against this background, we assessed the possible curative effects of long-term doxycycline administration in a mouse model of chronic CS exposure. Animals were exposed to cigarette smoke (CS) for 8 mo and then subsequently treated with doxycycline for additional 3 mo in room air conditions. Doxycycline decreased the expression of MMPs and general pro-inflammatory markers in the lungs from CS-exposed mice. This downregulation was, however, insufficient to ameliorate CS-induced emphysema or PH. Tet-On/Tet-Off induction by doxycycline in such models is a feasible genetic approach to study curative effects at least in established CS-induced emphysema and PH. However, we report several parameters that are influenced by doxycycline and use of a Tet-On/Tet-Off system when evaluating those parameters should be interpreted with caution.
- Published
- 2021
- Full Text
- View/download PDF
48. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension.
- Author
-
Gall H, Yogeswaran A, Fuge J, Sommer N, Grimminger F, Seeger W, Olsson KM, Hoeper MM, Richter MJ, Tello K, and Ghofrani HA
- Abstract
Background: Currently an echocardiographic threshold for the tricuspid regurgitation gradient (TRG) of > 31 mmHg is recommended for screening for pulmonary hypertension (PH). Invasively diagnosed PH was recently redefined as mean pulmonary arterial pressure (mPAP) > 20 mmHg instead of ≥ 25 mmHg. We investigated the ability of TRG to screen for the new PH-definition., Methods: Retrospective assessment of echocardiography and right heart catheterisation data from 1572 patients entering the Giessen PH-Registry during 2008-2018. Accuracy of different TRG thresholds and other echocardiographic parameters was evaluated using receiver operating characteristic curves., Findings: 1264 patients fulfilled the new PH-definition. Positive (PPV) and negative predictive values and accuracy of TRG > 46 mmHg were 95%, 39%, and 73%, respectively, for the new PH-definition. Lowering the TRG cut-off to 31 mmHg and below worsened PPV to ≤ 89%. The PPV of TRG for pre-capillary PH (mPAP > 20 mmHg and pulmonary vascular resistance ≥ 3 Wood Units) was ≤ 85%. In patients with TRG ≤ 46 mmHg, tricuspid annular plane systolic excursion/TRG and TRG/right ventricular outflow tract acceleration time were superior to TRG in screening for newly defined pre-capillary PH., Interpretation: In patients with suspected PH referred to a tertiary care centre, the PPV of TRG to meet the new PH-definition depended strongly on the TRG cut-off used. Our data do not support lowering the TRG cut-off. Combining TRG with other echocardiographic parameters might improve the validity of echocardiographic screening for PH., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
49. Mitochondrial Monoamine Oxidase: Another Player in Pulmonary Hypertension?
- Author
-
Sommer N and Schulz R
- Subjects
- Humans, Kinetics, Mitochondria metabolism, Monoamine Oxidase metabolism, Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Published
- 2021
- Full Text
- View/download PDF
50. Assessment of Short- and Medium-Chain Fatty Acids on Mitochondrial Function in Severe Inflammation.
- Author
-
Hecker M, Sommer N, and Mayer K
- Subjects
- DNA, Mitochondrial genetics, Fatty Acids chemistry, Fatty Acids, Volatile chemistry, Fatty Acids, Volatile pharmacology, Human Umbilical Vein Endothelial Cells, Humans, Inflammation pathology, Mitochondria pathology, Monocytes drug effects, Monocytes metabolism, Monocytes pathology, Tumor Necrosis Factor-alpha pharmacology, Fatty Acids pharmacology, Inflammation metabolism, Mitochondria drug effects, Mitochondria metabolism
- Abstract
Mitochondrial dysfunction is regarded as a key factor involved in the pathogenesis of septic disorders, leading to a decline in energy supply. The influence of short- and medium-chain fatty acids (SCFA/MCFA) on mitochondrial respiration under inflammatory conditions has thus far not been investigated. In the following protocol we describe the assessment of mitochondrial respiration using high-resolution respirometry under inflammatory and baseline conditions. For this approach, human endothelial cells and monocytes were pretreated with TNF-α to mimic inflammation followed by incubation with SCFA/MCFA and then subjected to high-resolution respirometry. Mitochondrial DNA content was assessed by PCR .
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.